Epigenetic upregulation of Schlafen11 renders WNT- and SHH-activated medulloblastomas sensitive to cisplatin
Neuro-Oncology · 2023
DOI: 10.1093/neuonc/noac243 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Satoshi Nakata und 39 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Medulloblastoma, Cerebellar Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Intramural NIH HHS, Japanese Society for Promotion of Science.
Abstract (Originalsprache)
Background
Intensive chemotherapeutic regimens with craniospinal irradiation have greatly improved survival in medulloblastoma patients. However, survival markedly differs among molecular subgroups and their biomarkers are unknown. Through unbiased screening, we found Schlafen family member 11 (SLFN11), which is known to improve response to DNA damaging agents in various cancers, to be one of the top prognostic markers in medulloblastomas. Hence, we explored the expression and functions of SLFN11 in medulloblastoma.
Methods
SLFN11 expression for each subgroup was assessed by immunohistochemistry in 98 medulloblastoma patient samples and by analyzing transcriptomic databases. We genetically or epigenetically modulated SLFN11 expression in medulloblastoma cell lines and determined cytotoxic response to the DNA damaging agents cisplatin and topoisomerase I inhibitor SN-38 in vitro and in vivo.
Results
High SLFN11 expressing cases exhibited significantly longer survival than low expressing cases. SLFN11 was highly expressed in the WNT-activated subgroup and in a proportion of the SHH-activated subgroup. While WNT activation was not a direct cause of the high expression of SLFN11, a specific hypomethylation locus on the SLFN11 promoter was significantly correlated with high SLFN11 expression. Overexpression or deletion of SLFN11 made medulloblastoma cells sensitive and resistant to cisplatin and SN-38, respectively. Pharmacological upregulation of SLFN11 by the brain-penetrant histone deacetylase-inhibitor RG2833 markedly increased sensitivity to cisplatin and SN-38 in SLFN11-negative medulloblastoma cells. Intracranial xenograft studies also showed marked sensitivity to cisplatin by SLFN11-overexpression in medulloblastoma cells.
Conclusions
High SLFN11 expression is one factor which renders favorable outcomes in WNT-activated and a subset of SHH-activated medulloblastoma possibly through enhancing response to cisplatin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Neurosurgery, Gunma University, Maebashi, Japan.
- Institute for Advanced Biosciences, Keio University, Tsuruoka, Japan.
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.
- Division of Neurosurgery, Department of Clinical Neuroscience, Faculty of Medicine University of Miyazaki, Miyazaki, Japan.
- Department of System Pathology for Neurological Disorders, Brain Research Institute, Niigata University, Niigata, Japan.
ORCID-Profile: Chihaya Imai, Charles G Eberhart, Manabu Natsumeda
Förderung
- NCI NIH HHS
- Intramural NIH HHS
- Japanese Society for Promotion of Science
- NIH grant
- National Cancer Institute
Zitieren
APA
Nakata, S., Murai, J., Okada, M., Takahashi, H., Findlay, T. H., Malebranche, K., Parthasarathy, A., Miyashita, S., Gabdulkhaev, R., Benkimoun, I., Druillennec, S., Chabi, S., Hawkins, E., Miyahara, H., Tateishi, K., Yamashita, S., Yamada, S., Saito, T., On, J., …, & Natsumeda, M. (2023). Epigenetic upregulation of Schlafen11 renders WNT- and SHH-activated medulloblastomas sensitive to cisplatin. Neuro-Oncology. https://doi.org/10.1093/neuonc/noac243
Vancouver
Nakata S, Murai J, Okada M, Takahashi H, Findlay TH, Malebranche K, et al. Epigenetic upregulation of Schlafen11 renders WNT- and SHH-activated medulloblastomas sensitive to cisplatin. Neuro-Oncology. 2023. doi:10.1093/neuonc/noac243
BibTeX
@article{Nakata2023,
author = {Nakata, Satoshi and Murai, Junko and Okada, Masayasu and Takahashi, Haruhiko and Findlay, Tyler H and Malebranche, Kristen and Parthasarathy, Akhila and Miyashita, Satoshi and Gabdulkhaev, Ramil and Benkimoun, Ilan and Druillennec, Sabine and Chabi, Sara and Hawkins, Eleanor and Miyahara, Hiroaki and Tateishi, Kensuke and Yamashita, Shinji and Yamada, Shiori and Saito, Taiki and On, Jotaro and Watanabe, Jun and Tsukamoto, Yoshihiro and Yoshimura, Junichi and Oishi, Makoto and Nakano, Toshimichi and Imamura, Masaru and Imai, Chihaya and Yamamoto, Tetsuya and Takeshima, Hideo and Sasaki, Atsuo T and Rodriguez, Fausto J and Nobusawa, Sumihito and Varlet, Pascale and Pouponnot, Celio and Osuka, Satoru and Pommier, Yves and Kakita, Akiyoshi and Fujii, Yukihiko and Raabe, Eric H and Eberhart, Charles G and Natsumeda, Manabu},
title = {Epigenetic upregulation of Schlafen11 renders WNT- and SHH-activated medulloblastomas sensitive to cisplatin},
journal = {Neuro-Oncology},
year = {2023},
doi = {10.1093/neuonc/noac243}
}
EUVIMED